Taking into consideration the various available radionuclides, it is apparent that the applicability of β--TRT in PSMA(+) PC depends on the nature of the tumours, stage of disease and the administered dose or radionuclide, which should allow for a dose high enough to destroy tumours but constrained to limit unspecific healthy tissue damage. Here, FOLH1 is linked to neoplasm.